{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:32:45Z","timestamp":1791347565113,"version":"4.3.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Febrile neutropenia (FN) is a serious complication of patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP-21. The prophylactic use of granulocyte colony\u2013stimulating factors (G-CSFs) can significantly reduce the risk of FN. International guidelines recommend G-CSFs for patients receiving chemotherapy with FN risk of 20% or 10 to 20% with defined risk factors. However, there are few studies on the incidence and risk factors of FN in patients with DLBCL receiving R-CHOP-21, especially in patients without primary G-CSF prophylaxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective analysis for the clinical data of 103 patients with DLBCL who underwent first R-CHOP-21 without primary G-CSF prophylaxis. The objective of the assessment was the incidence and risk factors of FN after the first chemotherapy cycle.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After the first chemotherapy cycle, the incidence of FN was 20.4%. Multivariate analysis showed that age\u2009\u2265\u200965\u00a0years, bone marrow involvement, albumin\u2009&lt;\u200935 g\/L, and average relative dose intensity\u2009\u2265\u200980% were independent risk factors for FN. According to risk factors, we created a risk score system. The incidence of FN in the low-, intermediate- and high-risk groups was 5.6%, 17.2%, and 61.9%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our data indicated that R-CHOP-21 itself is associated with a high-risk regiment for FN. We recommend that intermediate\/high-risk patients should actively consider primary G-CSF prophylaxis to reduce the incidence of FN after chemotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-023-08250-z","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T03:02:33Z","timestamp":1704942153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Incidence and risk factors for febrile neutropenia of patients with diffuse large B-cell lymphoma receiving R-CHOP-21 in China"],"prefix":"10.1007","volume":"32","author":[{"given":"Wenshuai","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longcan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"issue":"9","key":"8250_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384(9):842\u2013858. https:\/\/doi.org\/10.1056\/NEJMra2027612","journal-title":"N Engl J Med"},{"key":"8250_CR2","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood 116:2040\u20132045. https:\/\/doi.org\/10.1182\/blood-2010-03-276246","journal-title":"Blood"},{"key":"8250_CR3","doi-asserted-by":"publisher","unstructured":"Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP-21 study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 23:4117\u20134126. https:\/\/doi.org\/10.1200\/JCO.2005.09.131","DOI":"10.1200\/JCO.2005.09.131"},{"key":"8250_CR4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00520-011-1306-6","volume":"20","author":"R Pettengell","year":"2012","unstructured":"Pettengell R, Johnsen HE, Lugtenburg PJ, Silvestre AS, D\u00fchrsen U, Rossi FG, Schwenkglenks M, Bendall K, Szabo Z, Jaeger U (2012) Impact of febrile neutropenia on R-CHOP-21 chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer 20:647\u2013652. https:\/\/doi.org\/10.1007\/s00520-011-1306-6","journal-title":"Support Care Cancer"},{"key":"8250_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/1078155213492450","volume":"20","author":"D Weycker","year":"2014","unstructured":"Weycker D, Barron R, Kartashov A, Legg J, Lyman GH (2014) Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract 20:190\u2013198. https:\/\/doi.org\/10.1177\/1078155213492450","journal-title":"J Oncol Pharm Pract"},{"key":"8250_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00520-019-04802-4","volume":"28","author":"M Yokoyama","year":"2020","unstructured":"Yokoyama M, Kusano Y, Nishihara A, Inoue N, Nishimura N, Mishima Y, Terui Y, Nukada T, Nomura T, Hatake K (2020) Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP-21: 2-year experience in a single center (STOP FN in NHL 2). Support Care Cancer 28:571\u2013579. https:\/\/doi.org\/10.1007\/s00520-019-04802-4","journal-title":"Support Care Cancer"},{"key":"8250_CR7","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Inoue N, Nishimura N, Mishima Y, Terui Y, Nukada T, Nomura T, Hatake K (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor in febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158\u20133167. https:\/\/doi.org\/10.1200\/JCO.2006.08.8823","journal-title":"J Clin Oncol"},{"issue":"3","key":"8250_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00520-016-3468-8","volume":"25","author":"C Cerchione","year":"2017","unstructured":"Cerchione C, De Renzo A, Mr DP et al (2017) Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. Support Care Cancer 25(3):839\u2013845. https:\/\/doi.org\/10.1007\/s00520-016-3468-8","journal-title":"Support Care Cancer"},{"key":"8250_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.6004\/jnccn.2022.0026","volume":"20","author":"EA Griffiths","year":"2022","unstructured":"Griffiths EA, Roy V, Alwan L et al (2022) NCCN Guidelines\u00ae insights: hematopoietic growth factors, Version 1.2022. J Natl Compr Canc Netw 20:436\u2013442. https:\/\/doi.org\/10.6004\/jnccn.2022.0026","journal-title":"J Natl Compr Canc Netw"},{"key":"8250_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur J Cancer 47:8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"key":"8250_CR11","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J, Guidelines Committee ESMO (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27:v111\u2013v118. https:\/\/doi.org\/10.1093\/annonc\/mdw325","journal-title":"Ann Oncol"},{"key":"8250_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/10428190009089435","volume":"37","author":"T Intragumtornchai","year":"2000","unstructured":"Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D (2000) A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin\u2019s lmphoma. Leuk Lymphoma 37:351\u2013360. https:\/\/doi.org\/10.3109\/10428190009089435","journal-title":"Leuk Lymphoma"},{"key":"8250_CR13","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","volume":"22","author":"GH Lyman","year":"2004","unstructured":"Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin\u2019s lymphoma: a nationwide study. J Clin Oncol 22:4302\u20134311. https:\/\/doi.org\/10.1200\/JCO.2004.03.213","journal-title":"J Clin Oncol"},{"key":"8250_CR14","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1080\/1042819031000119262","volume":"44","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M, OPPS Working Group, ANC Study Group (2003) Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin\u2019s lymphoma receiving CHOP chemotherapy. Leuk Lymphom 44:2069\u20132076. https:\/\/doi.org\/10.1080\/1042819031000119262","journal-title":"Leuk Lymphom"},{"key":"8250_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.leukres.2012.02.002","volume":"36","author":"A Salar","year":"2012","unstructured":"Salar A, Haioun C, Rossi FG, Duehrsen U, Pettengell R, Johnsen HE, Jaeger U, Verhoef G, Schwenkglenks M, Bacon P, Bendall K, Lugtenburg PJ (2012) The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21-21: findings from clinical practice. Leuk Res 36:548\u2013553. https:\/\/doi.org\/10.1016\/j.leukres.2012.02.002","journal-title":"Leuk Res"},{"key":"8250_CR16","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3346\/jkms.2014.29.11.1493","volume":"29","author":"YW Choi","year":"2014","unstructured":"Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Jin UR, Park JS (2014) Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. J Korean Med Sci 29:1493\u20131500. https:\/\/doi.org\/10.3346\/jkms.2014.29.11.1493","journal-title":"J Korean Med Sci"},{"key":"8250_CR17","doi-asserted-by":"publisher","unstructured":"Chinese Society of Hematology, Chinese Medical Association; Chinese Medical Doctor Association, Hematology Branch (2020) Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever (2020). Zhonghua Xue Ye Xue Za Zhi 41:969-978. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2020.12.001","DOI":"10.3760\/cma.j.issn.0253-2727.2020.12.001"},{"key":"8250_CR18","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3760\/cma.j.issn.0253-2727.2020.12.001","volume":"16","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M, Szucs TD, Jackisch C, Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU) (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16:1299\u20131309. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2020.12.001","journal-title":"Support Care Cancer"},{"key":"8250_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3816\/CLM.2007.n.012","volume":"7","author":"DC Case Jr","year":"2007","unstructured":"Case DC Jr, Desch CE, Kalman LA, Vongkovit P, Mena RR, Fridman M, Allen B (2007) Community-based trial of R-CHOP-21 and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients. Clin Lymphoma Myeloma 7:354\u2013360. https:\/\/doi.org\/10.3816\/CLM.2007.n.012","journal-title":"Clin Lymphoma Myeloma"},{"key":"8250_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1365-2141.2008.07514.x","volume":"144","author":"R Pettengell","year":"2009","unstructured":"Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R, Paridaens R, Constenla M, Schwenkglenks M, Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU) (2009) Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INCEU Prospective Observational European Neutropenia Study. Br J Haematol 144:677\u2013685. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07514.x","journal-title":"Br J Haematol"},{"key":"8250_CR21","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1002\/cncr.11827","volume":"98","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Delgado DJ (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98:2402\u20132409. https:\/\/doi.org\/10.1002\/cncr.11827","journal-title":"Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08250-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08250-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08250-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T15:11:15Z","timestamp":1705417875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08250-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["8250"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08250-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the guidelines of the Declaration of Helsinki. This is a retrospective, anonymous analysis of clinical and epidemiological data only; thus, an ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable; informed consent was waived because of the retrospective nature of the study, and there were minimal risks to subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}